# An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Source: https://onco.cc/trials/nct02531516/  
OnCo record `nct02531516` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Apalutamide and Bicalutamide in prostate cancer, run by Aragon Pharmaceuticals, Inc., active and no longer recruiting.

## Summary

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS is a phase 3 interventional study registered as NCT02531516 by Aragon Pharmaceuticals, Inc., with 1503 participants enrolled, started 2015-11-19 and due to reach its primary completion in 2027-03-01. Interventions recorded: Apalutamide, Bicalutamide, Bicalutamide Placebo, Apalutamide Placebo, GnRH (agonist) and 74-80 Grays (units of radiation).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02531516
- Phase: 3
- Setting: ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
- Sponsor: Aragon Pharmaceuticals, Inc.
- Enrolled: 1503

## Sources

- ClinicalTrials.gov NCT02531516: https://clinicaltrials.gov/study/NCT02531516

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Apalutamide](https://onco.cc/drugs/apalutamide/), [Bicalutamide](https://onco.cc/drugs/bicalutamide/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct02531516.json